Australia's largest stock trading and investment forum Australia's #1 stock forum

SPL

0.00%

9.7¢ starpharma holdings limited

New indications for irinotecan, page-10

First 10 Last

Share
Profile

Follow
sarge17

3,450 Posts.

820

02/06/24

13:55

Post #: 74124784
Share

Originally posted by juxtaposer: ↑

The source of “Starpharma’s DEP Irinotecan combination cancer drug has shown to be superior to Onivyde” comes from research and presentations by Starpharma itself.

They have reported on the anti-cancer activity of their DEP® irinotecan in human colon and pancreatic cancer xenograft models, highlighting its advantages over conventional treatments.

Specifically, DEP® irinotecan incorporates the active irinotecan derivative SN-38, which avoids the need for hepatic conversion and is expected to accumulate preferentially in tumor tissue, exerting a superior anti-tumor effect1. This data was presented at the American Association for Cancer Research (AACR) and further detailed in a poster showcasing DEP® irinotecan’s combination data with leading anticancer therapies.Onivyde® (irinotecan liposome injection) is a prescription medicine used to treat adults with pancreatic cancer that has spread to other parts of the body.

The comparison between Starpharma’s DEP Irinotecan and Onivyde seems to be based on the enhanced efficacy and delivery mechanism of Starpharma’s product. For more detailed information, you can refer to the research and publications by Starpharma.

Expand

@juxtaposer this statement of yours (and of @antibotter ) below is misleading and should be considered to be without foundation and untrue unless you can back it up with a link/reference.

“The source of “Starpharma’s DEP Irinotecan combination cancer drug has shown to be superior to Onivyde” comes from research and presentations by Starpharma itself.”

Last edited by sarge17: 02/06/24

SPL Price at posting: 11.5¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 10 more messages in this thread...

First 10 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change 0.000(0.00%)		Mkt cap ! $40.48M

Open	High	Low	Value	Volume
9.9¢	9.9¢	9.5¢	$35.24K	364.0K

Buyers (Bids)

No.	Vol.	Price($)
3	18326	9.5¢

Sellers (Offers)

Price($)	Vol.	No.
9.8¢	15262	2

View Market Depth

No.	Vol.	Price($)
2	8326	0.095
3	160000	0.094
2	134306	0.092
3	81442	0.090
1	30000	0.089

Price($)	Vol.	No.
0.098	5000	1
0.100	38876	3
0.105	199768	2
0.110	168286	9
0.115	85453	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

SPL (ASX) Chart

New indications for irinotecan, page-10

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

New indications for irinotecan, page-10

Top Stories

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News